Novel immuno-oncologic therapies such as anti-CTLA-4 antibodies (ipilimumab) and anti-PD-1 antibodies (nivolumab and pembrolizumab) have recently achieved remarkable outcomes against advanced MM in clinical trials, with significant survival benefits and manageable safety outcomes 8-12. The gene discussed is PDCD1; the disease is Miyoshi myopathy.